Helping Cancer Patients Live Longer and Feel Better

Company Update - November 12, 2026



immuneering

NASDAQ: IMRX

FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS

This presentation contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding: Immuneering Corporation's (the "Company") plans to develop, manufacture and commercialize its product candidates; the treatment potential of its product candidates, including atebimetinib (also referred to as "atebi" and formerly known as IMM-1-104); the design, enrollment, and conduct of the Phase 3 clinical trial for atebimetinib; the ability of interim Phase 2a clinical data to support further development of atebimetinib and be confirmed as the trial progresses, including the safety, tolerability and potential efficacy of atebimetinib, alone or in combination with other therapeutic agents including modified gemcitabine/nab-paclitaxel ("mGnP"); the potential advantages and effectiveness of the Company's clinical and preclinical candidates; the timing of enrollment, completion and topline readout of MAPKeeper 301 and other earlier trials; the filing with, and approval by, regulatory authorities of the Company's product candidates; the evolving treatment and competitive landscape and how atebimetinib may fit in that treatment landscape; the sufficiency of funds to operate the business of the Company; statements regarding the Company's ability to advance its pipeline and further diversify its portfolio and make progress towards its goal of helping cancer patients live longer and feel better; the Company's cash needs and availability, including related to the Company's projected cash runway and current operating plans; and the plans and objectives of Company management for future operations, including with respect to the planning and execution of combination or potential pivotal clinical trials.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the period ended December 31, 2025 and Quarterly Report on Form 10-Q for the period ended September 30, 2026 filed with the SEC, and its other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent Company management's estimates as of the date of this presentation. While the Company may elect to update such forward-looking statements at some point in the future, other than as required by law it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

This presentation may also contain estimates and other statistical data made by independent parties and by the Company, including without limitation relating to market size and other data about the Company's industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of the Company's future performance and the future performance of the markets in which the Company operate are necessarily subject to a high degree of uncertainty and risk. Neither the Company nor its affiliates, advisors or representatives makes any representation as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation.

Unless otherwise specified, all clinical data in the following slides is based on an interim data collection from the intent-to-treat population of 55 patients dosed at the 320 mg once-daily dose level of atebimetinib in combination with modified gemcitabine/nab-paclitaxel ("mGnP" = 1,000 mg/m2 (Gem) + 125 mg/m2 (nab-Pac) days 1 & 15, every 4 weeks) in the Company's ongoing Phase 1/2a clinical trial, as of April 24, 2026. The median follow-up for overall survival (OS) was estimated by the reverse Kaplan–Meier method. All data remains subject to follow-up and database updates.

© Immuneering All Rights Reserved.

We Aim to Develop Cancer Medicines that Drive Long Survival with Outstanding Quality of Life for All-Comers

Our Aspirations	Atebi+mGnP Phase 2 Reported at ASCO, 1L PDAC	
Long Survival	**17.3**	**months median overall survival** (~2X benchmark)
Outstanding Quality of Life	**0**	**categories of Gr3+ TRAEs in ≥10% attributed to atebimetinib**, only 2 attributed to chemo
	84%	**of evaluable patients maintained or gained weight** at 3 months
All-Comers	**No genetic testing required**	**Responses** in G12D, G12V, G12R, G12L, G12A, Q61H, RAS other/unknown
	Broadly Combinable	**+mGnP:** reported **+FOLFIRINOX:** pending

What's Next

Clinical Guidance:

Phase 2 update in 1H 2027

Phase 3 now enrolling, NCT07562152

Phase 3 topline expected mid-2028

Lung cancer: atebi + anti-PD-1, dosing soon

Pancreatic cancer: atebi + CLDN18.2-targeted

Anaplastic thyroid cancer: atebi + chemo, BRAF-mutant and non-mutant

Other MAPK-driven tumors: *in planning*

Other oncogenic pathways: *preclinical pipeline*

Phase 2 data presented at ASCO in June 2026, data cutoff April 24, 2026. 1L = first-line; PDAC = pancreatic ductal adenocarcinoma; TRAE = treatment-related adverse event.


© Immuneering All Rights Reserved.

immuneering

Atebimetinib Addresses Two Key Liabilities in MEK Inhibition

Our First Target: MEK

Pulsatile ≥IC_{90} Inhibition with Once-Daily Oral Dosing



Healthy Cells = Intermittent

Cancer Cells = Continuous


Goals: Improve Tolerability, Expand Applicability to RAS Mutant Cancers

	Liabilities		Strengths	
1st Generation MEK inhibitors	Ineffective in cancers driven by **RAS**	Poorly tolerated	Effective in cancers driven by **RAF**	Counters Cachexia to preserve body mass
	corrected	improved	retained	retained
3rd Generation MEK inhibitor: Atebimetinib	**Block RAF-mediated MEK phosphorylation**	**Immuneering's Deep Cyclic Inhibitor (DCI) Technology**		

© Immuneering All Rights Reserved.

immuneering

We Believe Atebimetinib is Broadly Combinable



Supporting preclinical data to be presented at 2026 EORTC-NCI-AACR Symposium, November 19, 2026, 14:00–14:30 CET

© Immuneering All Rights Reserved.

immuneering

Announcement of Our Astellas Collaboration

Immuneering to Collaborate With Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients

- Collaboration aligns with Immuneering's expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -


- Represents Immuneering's fourth agreement with a pharma partner -

- Further expands external partnerships to bring innovative new combinations to patients -

© Immuneering All Rights Reserved.

CLDN18.2 is Frequently Expressed on Solid Tumors (30% of PDAC)

Percentage Expression by Tumor Type



Future Combination Partner Set

- Atebimetinib + chemo (light schedule)
- Atebimetinib ± chemo + CLDN18.2-targeted
- Atebimetinb ± chemo + PRMT5 inhibitor
- Atebimetinib ± chemo + G12D inhibitor
- Atebimetinib ± chemo + G12V inhibitor

Figure modified from Nikanjam et al, 2026, Clin Cancer Res. 2026 September 01; 32(17)

© Immuneering All Rights Reserved.
immuneering

Emerging Pre-clinical Data will Support the Combination of Atebimetinib and Chemotherapy in Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer – Preclinical Poster Presentation

Title: Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC)

Abstract Number: 144

Poster Number: PB-144

Presenter: Praveen Nair, Immuneering Corporation

Date: November 18, 2026

Session: Translational Studies

Supporting preclinical data to be presented at 2026 EORTC-NCI-AACR Symposium, November 18, 2026

© Immuneering All Rights Reserved.

immuneering

Dr. Alan Ho, MD, PhD – Memorial Sloan Kettering Cancer Center





© Immuneering All Rights Reserved.

immuneering

Anaplastic Thyroid Cancer Phase 2 Trial Design

Patient Population: Second-line (2L) anaplastic thyroid cancer (ATC)

Eligibility

- Histopathologically confirmed ATC with MAPK pathway alteration
- Molecular profiling by FDA-approved test
- ECOG performance status 0–2 (both cohorts)

- **Cohort A**: Progression on prior BRAF inhibitor plus MEK inhibitor required
- **Cohort B**: All Comers NOT otherwise eligible for Cohort A progressing on standard of care.


Safety Run-in (n=6)

Atebimetinib 320 mg PO QD (continuously)
+ Carboplatin AUC 5 IV Day 1 q21 days
+ Pemetrexed 500 mg/m² IV Day 1 q21 days

DLT evaluation period:

patients will be monitored for dose-limiting toxicities (DLTs) to assess tolerability of the combination and inform dose selection.

**The 6 patients in the safety run-in will be counted towards Cohort A and B



TREATMENT

Treatment regimen for Cohorts A and B will be the same as the Safety Run-In

Atebimetinib dose will be determined from the Safety Run-In

Endpoints

Primary
- ORR

Secondary
- DOR
- DCR
- PFS
- Safety
- OS

© Immuneering All Rights Reserved.
immuneering

Immuneering's Pipeline

Indication	Regimen	Phase 1/2	Phase 3	Reg.	Collaboration
1L PDAC	Atebimetinib + mGnP vs. GnP	**Phase 3 – registrational intent**			Immuneering only
1L PDAC	Atebi + FFX	**Phase 2 · Efficacy**			Immuneering only
1L PDAC	CLDN18.2-targeted + atebi + mGnP (biomarker-positive)	**Phase 1b · Efficacy**			Astellas
2L, 3L PDAC (chemo-free)	CLDN18.2-targeted + atebi (chemo-free; biomarker-positive)	**Phase 1/2 · Efficacy**			Astellas
1L RAS-mut NSCLC	Atebi + cemiplimab ± chemo	**Phase 2 · Efficacy**			Regeneron
2L/3L RAS-G12C NSCLC	Atebi + olomorasib	**Phase 2 · Efficacy**			Eli Lilly
2L Anaplastic Thyroid Cancer	Atebi + chemo	**Phase 2 – reg'l intent**			Immuneering only

More atebimetinib combinations under discussion

atebi, atebimetinib (IMM-1-104); PDAC, pancreatic ductal adenocarcinoma; NSCLC, non-small cell lung cancer; (m)GnP, (modified) gemcitabine + nab-paclitaxel; (m)FFX, (modified) FOLFIRINOX; ATC, anaplastic thyroid cancer, SoC, standard of care; KoL, key opinion leader; 1L/2L/3L, first/second /thirdline.

© Immuneering All Rights Reserved.

immuneering

Q & A

immuneering